Ajax loader
By using our website, you agree to our use of cookies as described in Cookie Policy.

Can't find what you're looking for?

 

Be sure to Sign in to see all available content.

 

If you don't have an account, Register here.

Search results for: Leiden-(City)

NETHERLANDS-UNIVERSITY/
RTS13NCV
April 24, 2017
View of the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala Olivares...
Leiden, Netherlands
View of the campus of the University of Leiden
View of the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala Olivares
NETHERLANDS-UNIVERSITY/
RTS13NCU
April 24, 2017
Students rides bikes at the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris...
Leiden, Netherlands
Students rides bikes at the campus of the University of Leiden
Students rides bikes at the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala Olivares
NETHERLANDS-UNIVERSITY/
RTS13NCT
April 24, 2017
Students meet at the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala...
Leiden, Netherlands
Students meet at the campus of the University of Leiden
Students meet at the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala Olivares
NETHERLANDS-UNIVERSITY/
RTS13NCS
April 24, 2017
Students meet near the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris...
Leiden, Netherlands
Students meet near the campus of the University of Leiden
Students meet near the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala Olivares
NETHERLANDS-UNIVERSITY/
RTS13NCR
April 24, 2017
Students meet near the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris...
Leiden, Netherlands
Students meet near the campus of the University of Leiden
Students meet near the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala Olivares
NETHERLANDS-UNIVERSITY/
RTS13NCP
April 24, 2017
Students work in the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala...
Leiden, Netherlands
Students work in the campus of the University of Leiden
Students work in the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala Olivares
NETHERLANDS-UNIVERSITY/
RTS13NCO
April 24, 2017
A student reads a book at the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris...
Leiden, Netherlands
A student reads a book at the campus of the University of Leiden
A student reads a book at the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala Olivares
NETHERLANDS-UNIVERSITY/
RTS13NCN
April 24, 2017
Students sit in a park in the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris...
Leiden, Netherlands
Students sit in a park in the campus of the University of Leiden
Students sit in a park in the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala Olivares
NETHERLANDS-UNIVERSITY/
RTS13NCL
April 24, 2017
Students meet at the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala...
Leiden, Netherlands
Students meet at the campus of the University of Leiden
Students meet at the campus of the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala Olivares
NETHERLANDS-UNIVERSITY/
RTS13NCK
April 24, 2017
Bikes are parked near an entrance of the campus at the University of Leiden, Netherlands, March 27, 2017....
Leiden, Netherlands
Bikes are parked near an entrance of the campus at the University of Leiden
Bikes are parked near an entrance of the campus at the University of Leiden, Netherlands, March 27, 2017. REUTERS/Cris Toala Olivares
NETHERLANDS-ELECTION/
RTX30WXM
March 14, 2017
An election poster is seen outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan...
Leiden, Netherlands
An election poster is seen outside a train station in Leiden
An election poster is seen outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WXF
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WXC
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WX9
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WUP
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WT5
March 14, 2017
A man cycles by an election poster outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan...
Leiden, Netherlands
A man cycles by an election poster outside a train station in Leiden
A man cycles by an election poster outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WSL
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WSI
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WS4
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WRR
March 14, 2017
A supporter holds a placard showing Dutch Green Party (Groen Links) leader Jesse Klaver outside a train...
Leiden, Netherlands
A supporter holds a placard showing Dutch Green Party (Groen Links) leader Jesse Klaver outside a train...
A supporter holds a placard showing Dutch Green Party (Groen Links) leader Jesse Klaver outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WRM
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WR0
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WQZ
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WQ7
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WQ4
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver holds a leaflet showing his face while campaigning...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver holds a leaflet showing his face while campaigning outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez TPX IMAGES OF THE DAY
NETHERLANDS-ELECTION/
RTX30WPH
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver greets a Muslim supporter while campaigning outside...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver greets a Muslim supporter while campaigning outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WPF
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver poses with supporters of the D66 party while campaigning...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver poses with supporters of the D66 party while campaigning outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WOW
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WOH
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WOA
March 14, 2017
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands...
Leiden, Netherlands
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden
Dutch Green Party (Groen Links) leader Jesse Klaver campaigns outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
NETHERLANDS-ELECTION/
RTX30WKI
March 14, 2017
A man cycles by an election poster outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan...
Leiden, Netherlands
A man cycles by an election poster outside a train station in Leiden
A man cycles by an election poster outside a train station in Leiden, Netherlands March 14, 2017. REUTERS/Dylan Martinez
IKEA-RESTRUCTURING/ 
RTX2A1W9
April 15, 2016
INGKA Holding's Chief Executive Officer Peter Agnefjall poses for a photograph at the IKEA Group headquarters...
Leiden, Netherlands
INGKA Holding's CEO Peter Agnefjall poses for a photograph at the IKEA Group headquarters in Leiden
INGKA Holding's Chief Executive Officer Peter Agnefjall poses for a photograph at the IKEA Group headquarters in Leiden, the Netherlands March 14, 2016. REUTERS/Tom Bergin
IKEA-RESTRUCTURING/ 
RTX2A1W6
April 15, 2016
Exterior view of the IKEA Group headquarters in Leiden, the Netherlands, March 14, 2016. REUTERS/Tom...
Leiden, Netherlands
Exterior view of the IKEA Group headquarters in Leiden
Exterior view of the IKEA Group headquarters in Leiden, the Netherlands, March 14, 2016. REUTERS/Tom Bergin
IKEA-RESTRUCTURING/ 
RTX2A1W5
April 15, 2016
INGKA Holding's CEO Peter Agnefjall poses for a photograph at the IKEA Group headquarters in Leiden,...
Leiden, Netherlands
INGKA Holding's CEO Peter Agnefjall poses for a photograph at the IKEA Group headquarters in Leiden
INGKA Holding's CEO Peter Agnefjall poses for a photograph at the IKEA Group headquarters in Leiden, the Netherlands March 14, 2016. REUTERS/Tom Bergin
IKEA-RESTRUCTURING/ 
RTX2A1W3
April 15, 2016
INGKA Holding's CEO Peter Agnefjall poses for Reuters at the IKEA Group headquarters in Leiden, the Netherlands...
Leiden, Netherlands
INGKA Holding's CEO Peter Agnefjall poses for Reuters at the IKEA Group headquarters in Leiden
INGKA Holding's CEO Peter Agnefjall poses for Reuters at the IKEA Group headquarters in Leiden, the Netherlands March 14, 2016. REUTERS/Tom Bergin
DUTCH-ELECTION//
RTR37V8Z
September 12, 2012
Socialist Party Leader Diederik Samsom casts his ballot for the Netherlands' general election as his...
Leiden, Netherlands
Socialist Party Leader Diederik Samsom casts his ballot for the Netherlands' general election as his...
Socialist Party Leader Diederik Samsom casts his ballot for the Netherlands' general election as his son Fane (L) plays with a red pencil at a voting booth in Leiden September 12, 2012. REUTERS/Michael Kooren (NETHERLANDS - Tags: POLITICS ELECTIONS)
DUTCH-POLITICS/POLL
RTR37V8O
September 12, 2012
Labour Party leader Diederik Samsom and his wife Tineke Hoogenboom (2nd R, behind Samsom) take their...
Leiden, Netherlands
Labour Party leader Samsom and his wife Hoogenboom take their children Benthe and Fane to school after...
Labour Party leader Diederik Samsom and his wife Tineke Hoogenboom (2nd R, behind Samsom) take their children Benthe (C) and Fane (R) to school after casting their ballot for the Netherlands' general election at a voting station in Leiden September 12, 2012. Two pro-European Dutch political parties were neck-and-neck in the latest opinion polls before a parliamentary election dominated by the euro zone crisis started on Wednesday. REUTERS/Michael Kooren (NETHERLANDS - Tags: POLITICS ELECTIONS)
DUTCH-POLITICS/
RTR37V8L
September 12, 2012
Socialist Party Leader Diederik Samsom (C) is surrounded by members of the media after casting his ballot...
Leiden, Netherlands
Socialist Party Leader Samsom is surrounded by members of the media after casting his ballot in Netherlands'...
Socialist Party Leader Diederik Samsom (C) is surrounded by members of the media after casting his ballot in Netherlands' general election at a voting station in Leiden September 12, 2012. REUTERS/Michael Kooren (NETHERLANDS - Tags: POLITICS ELECTIONS MEDIA)
DUTCH-POLITICS/POLL
RTR37V8B
September 12, 2012
Labour Party leader Diederik Samsom holds his daughter Benthe's hand as he speaks to the press after...
Leiden, Netherlands
Labour Party leader Samsom holds his daughter Benthe's hand as he speaks to the press after casting his...
Labour Party leader Diederik Samsom holds his daughter Benthe's hand as he speaks to the press after casting his ballot in the Netherlands' general election at a voting station in Leiden September 12, 2012. Two pro-European Dutch political parties were neck-and-neck in the latest opinion polls before a parliamentary election dominated by the euro zone crisis started on Wednesday. REUTERS/Michael Kooren (NETHERLANDS - Tags: POLITICS ELECTIONS)
DUTCH-POLITICS/POLL
RTR37V89
September 12, 2012
Labour Party leader Diederik Samsom casts his ballot in the Netherlands' general election beside his...
Leiden, Netherlands
Labour Party leader Samsom casts his ballot in the Netherlands' general election beside his children...
Labour Party leader Diederik Samsom casts his ballot in the Netherlands' general election beside his children Fane (L) and Benthe (2nd R) at a voting station in Leiden September 12, 2012. Two pro-European Dutch political parties were neck-and-neck in the latest opinion polls before a parliamentary election dominated by the euro zone crisis started on Wednesday. REUTERS/Michael Kooren (NETHERLANDS - Tags: POLITICS ELECTIONS)
DUTCH-POLITICS/POLL
RTR37V88
September 12, 2012
Labour Party leader Diederik Samsom shows his children Benthe (L) and Fane (R) the list of candidates...
Leiden, Netherlands
Labour Party leader Samsom shows his children Benthe and Fane the list of candidates before he casts...
Labour Party leader Diederik Samsom shows his children Benthe (L) and Fane (R) the list of candidates before he casts his ballot in the Netherlands' general election at a voting station in Leiden September 12, 2012. Two pro-European Dutch political parties were neck-and-neck in the latest opinion polls before a parliamentary election dominated by the euro zone crisis started on Wednesday. REUTERS/Michael Kooren (NETHERLANDS - Tags: POLITICS ELECTIONS)
DUTCH-POLITICS/POLL
RTR37V85
September 12, 2012
Labour Party leader Diederik Samsom casts his ballot in the Netherlands' general election at a voting...
Leiden, Netherlands
Labour Party leader Samsom casts his ballot in the Netherlands' general election at a voting station...
Labour Party leader Diederik Samsom casts his ballot in the Netherlands' general election at a voting station in Leiden September 12, 2012. Two pro-European Dutch political parties were neck-and-neck in the latest opinion polls before a parliamentary election dominated by the euro zone crisis started on Wednesday. REUTERS/Michael Kooren (NETHERLANDS - Tags: POLITICS ELECTIONS)
DUTCH-POLITICS/POLL
RTR37V83
September 12, 2012
Labour Party leader Diederik Samsom casts his ballot in the Netherlands' general election as his son...
Leiden, Netherlands
Labour Party leader Samsom casts his ballot in the Netherlands' general election as his son Fane plays...
Labour Party leader Diederik Samsom casts his ballot in the Netherlands' general election as his son Fane (L) plays with a red pencil at a voting station in Leiden September 12, 2012. Two pro-European Dutch political parties were neck-and-neck in the latest opinion polls before a parliamentary election dominated by the euro zone crisis started on Wednesday. REUTERS/Michael Kooren (NETHERLANDS - Tags: POLITICS ELECTIONS)
DUTCH-POLITICS/POLL
RTR37V81
September 12, 2012
Labour Party leader Diederik Samsom (R) casts his ballot in the Netherlands' general election with his...
Leiden, Netherlands
Labour Party leader Samsom casts his ballot in the Netherlands' general election with his children Fane...
Labour Party leader Diederik Samsom (R) casts his ballot in the Netherlands' general election with his children Fane (L) and Benthe at a voting station in Leiden September 12, 2012. Two pro-European Dutch political parties were neck-and-neck in the latest opinion polls before a parliamentary election dominated by the euro zone crisis started on Wednesday. REUTERS/Michael Kooren (NETHERLANDS - Tags: POLITICS ELECTIONS)
DUTCH-POLITICS/POLL
RTR37V7X
September 12, 2012
Labour Party leader Diederik Samsom (C) arrives at the voting station with his family to cast his ballot...
Leiden, Netherlands
Labour Party leader Samsom arrives at the voting station with his family to cast his ballot in the Netherlands'...
Labour Party leader Diederik Samsom (C) arrives at the voting station with his family to cast his ballot in the Netherlands' general election in Leiden September 12, 2012. Two pro-European Dutch political parties were neck-and-neck in the latest opinion polls before a parliamentary election dominated by the euro zone crisis started on Wednesday. REUTERS/Michael Kooren (NETHERLANDS - Tags: POLITICS ELECTIONS)
DUTCH-POLITICS/POLL
RTR37V7W
September 12, 2012
Labour Party leader Diederik Samsom casts his ballot in the Netherlands' general election at a voting...
Leiden, Netherlands
Labour Party leader Samsom casts his ballot in the Netherlands' general election at a voting station...
Labour Party leader Diederik Samsom casts his ballot in the Netherlands' general election at a voting station in Leiden September 12, 2012. Two pro-European Dutch political parties were neck-and-neck in the latest opinion polls
before a parliamentary election dominated by the euro zone crisis started on Wednesday. REUTERS/Michael Kooren (NETHERLANDS - Tags: POLITICS ELECTIONS)
BIOTECHNOLOGY-EUROPE/
RTR2J0VP
February 24, 2011
A Dutch-based biotech, Prosensa, researcher works on developing, possibly the World's first treatment...
Leiden, Netherlands
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
A Dutch-based biotech, Prosensa, researcher works on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)
BIOTECHNOLOGY-EUROPE/
RTR2J0VO
February 24, 2011
A Dutch-based biotech, Prosensa, researcher work on developing, possibly the World's first treatment...
Leiden, United Kingdom
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
A Dutch-based biotech, Prosensa, researcher work on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike.To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)
BIOTECHNOLOGY-EUROPE/
RTR2J0VJ
February 24, 2011
A Dutch-based biotech, Prosensa, researcher works on developing, possibly the World's first treatment...
Leiden, Netherlands
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
A Dutch-based biotech, Prosensa, researcher works on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)
BIOTECHNOLOGY-EUROPE/
RTR2J0VG
February 24, 2011
A Dutch-based biotech, Prosensa, researcher works on developing, possibly the World's first treatment...
Leiden, Netherlands
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
A Dutch-based biotech, Prosensa, researcher works on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)
BIOTECHNOLOGY-EUROPE/
RTR2J0VE
February 24, 2011
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for...
Leiden, Netherlands
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)
BIOTECHNOLOGY-EUROPE/
RTR2J0VC
February 24, 2011
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for...
Leiden, Netherlands
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)
BIOTECHNOLOGY-EUROPE/
RTR2J0VB
February 24, 2011
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for...
Leiden, Netherlands
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)
BIOTECHNOLOGY-EUROPE/
RTR2J0V9
February 24, 2011
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for...
Leiden, Netherlands
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS)
BIOTECHNOLOGY-EUROPE/
RTR2J0V7
February 24, 2011
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for...
Leiden, Netherlands
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)
BIOTECHNOLOGY-EUROPE/
RTR2J0V3
February 24, 2011
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for...
Leiden, multiple countries
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)
BIOTECHNOLOGY-EUROPE/
RTR2J0V2
February 24, 2011
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for...
Leiden, Netherlands
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)
BIOTECHNOLOGY-EUROPE/
RTR2J0V0
February 24, 2011
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for...
Leiden, Netherlands
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)
BIOTECHNOLOGY-EUROPE/
RTR2J0UY
February 24, 2011
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for...
Leiden, Netherlands
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)
BIOTECHNOLOGY-EUROPE/
RTR2J0UX
February 24, 2011
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for...
Leiden, multiple countries
To match ANALYSIS BIOTECHNOLOGY-EUROPE/
Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)
Sort by
Display
Items per page
Page
of 2